PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11020758-0	2000	Block of human heart hH1 sodium channels by the enantiomers of bupivacaine.	Bupivacaine	63-74	H1.5 linker histone, cluster member	Homo sapiens	21-24	
11020758-2	2000	The bupivacaine binding site in human heart (hH1) Na+ channels has not been studied to date.	Bupivacaine	4-15	H1.5 linker histone, cluster member	Homo sapiens	45-48	
11020758-7	2000	In mutations hH1-F1760K and hH1-N1765K, bupivacaine affinity of inactivated channels was reduced by approximately 20- to 40-fold, in mutation hH1-N406K by approximately sevenfold, and in mutations hH1-Y1767K and hH1-Y1767D by approximately twofold to threefold.	Bupivacaine	40-51	H1.5 linker histone, cluster member	Homo sapiens	13-16	
11020758-7	2000	In mutations hH1-F1760K and hH1-N1765K, bupivacaine affinity of inactivated channels was reduced by approximately 20- to 40-fold, in mutation hH1-N406K by approximately sevenfold, and in mutations hH1-Y1767K and hH1-Y1767D by approximately twofold to threefold.	Bupivacaine	40-51	H1.5 linker histone, cluster member	Homo sapiens	28-31	
11020758-7	2000	In mutations hH1-F1760K and hH1-N1765K, bupivacaine affinity of inactivated channels was reduced by approximately 20- to 40-fold, in mutation hH1-N406K by approximately sevenfold, and in mutations hH1-Y1767K and hH1-Y1767D by approximately twofold to threefold.	Bupivacaine	40-51	H1.5 linker histone, cluster member	Homo sapiens	28-31	
11020758-7	2000	In mutations hH1-F1760K and hH1-N1765K, bupivacaine affinity of inactivated channels was reduced by approximately 20- to 40-fold, in mutation hH1-N406K by approximately sevenfold, and in mutations hH1-Y1767K and hH1-Y1767D by approximately twofold to threefold.	Bupivacaine	40-51	H1.5 linker histone, cluster member	Homo sapiens	28-31	
11020758-7	2000	In mutations hH1-F1760K and hH1-N1765K, bupivacaine affinity of inactivated channels was reduced by approximately 20- to 40-fold, in mutation hH1-N406K by approximately sevenfold, and in mutations hH1-Y1767K and hH1-Y1767D by approximately twofold to threefold.	Bupivacaine	40-51	H1.5 linker histone, cluster member	Homo sapiens	28-31	
11020758-11	2000	Amino acid residues in positions hH1-F1760, hH1-N1765, and hH1-N406 may contribute to binding of bupivacaine enantiomers in hH1 Na+ channels, whereas the role of hH1-Y1767 remains unclear.	Bupivacaine	97-108	H1.5 linker histone, cluster member	Homo sapiens	33-36	
11020758-11	2000	Amino acid residues in positions hH1-F1760, hH1-N1765, and hH1-N406 may contribute to binding of bupivacaine enantiomers in hH1 Na+ channels, whereas the role of hH1-Y1767 remains unclear.	Bupivacaine	97-108	H1.5 linker histone, cluster member	Homo sapiens	44-47	
11020758-11	2000	Amino acid residues in positions hH1-F1760, hH1-N1765, and hH1-N406 may contribute to binding of bupivacaine enantiomers in hH1 Na+ channels, whereas the role of hH1-Y1767 remains unclear.	Bupivacaine	97-108	H1.5 linker histone, cluster member	Homo sapiens	44-47	
11020758-11	2000	Amino acid residues in positions hH1-F1760, hH1-N1765, and hH1-N406 may contribute to binding of bupivacaine enantiomers in hH1 Na+ channels, whereas the role of hH1-Y1767 remains unclear.	Bupivacaine	97-108	H1.5 linker histone, cluster member	Homo sapiens	44-47	
11020758-11	2000	Amino acid residues in positions hH1-F1760, hH1-N1765, and hH1-N406 may contribute to binding of bupivacaine enantiomers in hH1 Na+ channels, whereas the role of hH1-Y1767 remains unclear.	Bupivacaine	97-108	H1.5 linker histone, cluster member	Homo sapiens	44-47	
3415889-3	1988	infusion of either physiological saline or 0.25% bupivacaine 20 ml h-1 (in saline) following a loading dose of saline 1 ml kg-1 or 0.25% bupivacaine 1 ml kg-1 on entering the peritoneum.	Bupivacaine	49-60	H1.5 linker histone, cluster member	Homo sapiens	67-70	
3828182-0	1987	Extradural infusion of 0.125% bupivacaine at 10 ml h-1 to women during labour.	Bupivacaine	30-41	H1.5 linker histone, cluster member	Homo sapiens	51-54